

Resource Summary Report

Generated by [RRID](#) on Aug 27, 2026

Lenti-dCas9-KRAB-blast

RRID:Addgene_89567

Type: Plasmid

Proper Citation

RRID:Addgene_89567

Plasmid Information

URL: <http://www.addgene.org/89567>

Proper Citation: RRID:Addgene_89567

Insert Name: dCas9

Organism: Synthetic

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:28416141](#)

Vector Backbone Description: Vector Backbone:plenti; Vector Types:Lentiviral; Bacterial Resistance:Ampicillin

Plasmid Name: Lenti-dCas9-KRAB-blast

Relevant Mutation: D10A and H840A

Record Creation Time: 20220422T222609+0000

Record Last Update: 20260815T082158+0000

Ratings and Alerts

No rating or validation information has been found for Lenti-dCas9-KRAB-blast.

No alerts have been found for Lenti-dCas9-KRAB-blast.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 86 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Shi W, et al. (2026) CRISPR screens identify PRMT7 as a therapeutic target to enhance T cell-mediated killing in breast cancer. NPJ breast cancer, 12(1), 24.

Sivakumaran H, et al. (2026) BRRIAR lncRNA alters breast cancer risk by modulating interferon signaling in cis and in trans. Molecular cancer, 25(1), 5.

Jiang Y, et al. (2026) The castration-resistant prostate cancer-associated SNP rs11067228 facilitates neuroendocrine differentiation through an enhancer-mediated chromatin interaction with SRRM4. International journal of biological sciences, 22(3), 1440.

Abou Alaiwi S, et al. (2026) Generation of a comprehensive epigenomic atlas in clear cell renal cell carcinoma informs kidney cancer progression and heritability. Cell reports, 45(2), 116968.

Friske JD, et al. (2026) A Conserved Enhancer Locus in Extrachromosomal DNA and Homogeneously Staining Regions Activates MYC Transcription in Group 3 Medulloblastoma. Cancer research, 86(13), 3160.

Nag D, et al. (2026) A single mycobacterial ligand organizes multi-receptor signaling to reprogram macrophage lipid metabolism. bioRxiv : the preprint server for biology.

Wang Z, et al. (2026) Multidimensional mapping of stimulation-responsive regulatory elements and candidate causal variants in T cell activation. Science advances, 12(1), eady2539.

Cui X, et al. (2025) Comparative characterization of human accelerated regions in neurons. Nature, 640(8060), 991.

Kaushik K, et al. (2025) Requirements for the neurodevelopmental disorder-associated gene ZNF292 in human cortical interneuron development and function. Cell reports, 44(5), 115597.

Malekos E, et al. (2025) CRISPRware: a software package for contextual gRNA library design. BMC genomics, 26(1), 607.

Xu S, et al. (2025) SWI/SNF complex-mediated ZNF410 cooperative binding maintains chromatin accessibility and enhancer activity. Cell reports, 44(4), 115476.

Gambi G, et al. (2025) 3D chromatin hubs as regulatory units of identity and survival in human acute leukemia. Molecular cell, 85(1), 42.

Matoba N, et al. (2025) Massively parallel assessment of gene regulatory activity at human cortical structure associated variants. bioRxiv : the preprint server for biology.

Li J, et al. (2025) CREPT is required for the metastasis of triple-negative breast cancer through a co-operational-chromatin loop-based gene regulation. *Molecular cancer*, 24(1), 170.

Yang H, et al. (2025) Oxytocin Receptor Regulates the Hippo/YAP Axis to Drive Hepatocarcinogenesis. *Cancer research*, 85(19), 3752.

Zhao K, et al. (2025) Endogenous fine-mapping and prioritization of functional regulatory elements in complex genetic loci. *Cell genomics*, 100982.

Wang Y, et al. (2025) Enhancer regulatory networks globally connect non-coding breast cancer loci to cancer genes. *Genome biology*, 26(1), 10.

John K, et al. (2025) Human long noncoding RNA VILMIR is induced by major respiratory viral infections and modulates the host interferon response. *Journal of virology*, 99(4), e0014125.

Matkar S, et al. (2025) Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma. *Molecular cancer therapeutics*, 24(9), 1389.

Grinshpun A, et al. (2024) Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer. *NPJ breast cancer*, 10(1), 42.